Shares of CRISPR Therapeutics AG (:CRSP) currently have an average target price of $64.69. This is the consensus number using estimates provided by polled analysts. Street analysts often give price target projections on stocks that they track. Price target projections can be calculated using a variety of methods. Many investors will follow stock target prices, especially when analysts make revisions. A thorough research report will typically provide detailed reasoning for a certain target projection. Some investors may watch sell-side targets very closely and use the information to assist with their own stock analysis.
Investors are constantly looking for ways to find success in the stock market. Figuring out what stocks to buy can be tough. With so many different names to choose from, the task can seem quite overwhelming at times. Many investors will opt to go with a mix of growth and value stocks. Investors looking to capitalize on shorter-term price movements may have a completely different game plan than those who are looking to fin stocks to hold onto for the longer-term. Finding quality stocks that match the individual’s criteria may take a lot of effort and dedication, but it may be well worth it for the long-term success of the portfolio.
Taking a quick look at analyst opinions, we can see that the current average broker recommendation on shares of CRISPR Therapeutics AG (:CRSP) is presently 2.18. Out of the covering analysts polled by Zacks Research, 7 have put a Strong Buy or Buy rating on the stock.
As earnings season comes into focus, investors will be closely tracking sell-side estimates. According to analysts polled by Zacks Research, the current quarter EPS consensus estimate is currently sitting at -0.89 for shares of CRISPR Therapeutics AG (:CRSP). The number consists of estimates provided by 3 contributing analysts. For the last reporting period, the company posted a quarterly EPS of -1.07. The consensus estimate for last quarter before the earnings report was -0.78. Looking out further to the next quarter EPS estimate, the consensus is currently resting at -0.95. This consensus estimate includes 3 analysts taken into consideration by Zacks. Shifting the focus to the current fiscal year EPS estimate, the number is currently -3.26. Widening the gaze to the next fiscal year, we can see that the consensus EPS estimate is presently -3.47.
Checking in on stock price activity for CRISPR Therapeutics AG (:CRSP), we have recently seen shares trading near the $32.29 mark. Investors will often track the current stock price in relation to its 52-week high and low levels. The 52-week high is currently $73.59, and the 52-week low is presently $22.73. When the current stock price is trading close to either the 52-week high or 52-week low, investors may pay closer attention to see if there will be a breakthrough that level. Over the past 12 weeks, the stock has seen a change of -9.27%. Going back to the start of the calendar year, we can see that shares have moved 13.02%. Pulling the focus closer to the past 4 weeks, shares have seen a change of 22.26%. Over the past 5 trading days, the stock has moved -10.01%.
New traders may face many challenges when entering the stock market. One of the bigger challenges involves not repeating mistakes. As with any new endeavor, there will be a learning curve. Paying attention to historical trades can help the trader figure out where they might have gone astray. Repeating the same mistakes over and over again can lead to the demise of the trader’s confidence and hard earned money. Traders who are able to move forward and learn from previous errors may find themselves making much better decisions in the future.